U of Pittsburgh to use Aposense technology for brain cancer trials
Aposense has signed a material transfer agreement with the University of Pittsburgh, in which the university will have the right to use Aposense technology in a clinical trial in patients with glioblastoma multiforme type brain cancer funded by the National Institutes of Health (NIH).

The clinical data on the EarliTest imaging solution collected during the study may aid Aposense in its future regulatory submission to the FDA, said the Petach-Tikva, Israel-based company. EarliTest uses a radioactive labeled compound 18F-ML-10 that allows imaging of the response of a cancerous tumor early during the course of anticancer treatments. The trial will be led by James M. Mountz, MD, PhD, chief of nuclear medicine at the University of Pittsburgh.

Aposense also has signed collaboration agreements with GlaxoSmithKline and Roche, according to which the companies will use EarliTest for molecular imaging in clinical trials in which the efficacy of new oncological treatments will be tested.